Estimation of Level of ERAP1 Expression in Lesional and Non Lesional Skin of Psoraitic Patients and Healthy Controls.

Kasr El Aini Hospital

Status: Completed

Conditions: Psoriasis

Treatments: Diagnostic Test: RT-PCR for ERAP1 detection

Study type: Interventional

Funder types: Other

Identifiers

NCT03767114

EgyERAP

Details and patient eligibility

About

A 4mm Punch biopsy is obtained from lesional and non lesional skin of 25 psoraitic patients as well as of 30 controls.

Skin biopsy from patients (psoriasis lesional and non lesional) & control will be kept in lysis solution (which contains RNAase inhibitor) for the stability of the parameter to be assessed. ERAP-1 gene expression will Research Template 5 Final Version: 8/3/2 016 be detected by quantitative real time -PCR, which include RNA extraction, cDNA synthesis & PCR.

Enrollment: 55 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients with psoriasis vulgaris
• patients over 18 years of age
• both sexes

Exclusion criteria

• patients on treatment for psoriasis within the last two months
• assoiciated autoimmune diseases eg SLE
• pregnancy

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

55 participants in 2 patient groups

cases of psoriasis

Experimental group

Description:

group of 25 cases of psoriasis subjected to skin biopsy for detection of lesional and non lesional expression of ERAP1 by RT-PCR

Treatment:

Diagnostic Test: RT-PCR for ERAP1 detection

normal controls

Experimental group

Description:

group of 30 age and sex matched healthy controls o subjected to skin biopsy from normal skin for detection of expression of ERAP1 by RT-PCR

Treatment:

Diagnostic Test: RT-PCR for ERAP1 detection